NewAmsterdam Pharma: CAO Sold $6.7M, Stock Below Floor.
NewAmsterdam Pharma's CAO sold $6.71 million in shares across three months at prices between $29.96 and $35.69, and the stock now trades at $27.79, below her lowest exit price. The analyst consensus t
NAMS CAO Sold $6.7M Above $29; Shares Now at $27.79
NEW YORK, August 21 —
NewAmsterdam Pharma Company N.V. (NAMS) presents a clean test of what insider selling actually signals: its Chief Accounting Officer liquidated $6.71 million in shares across three months at prices between $29.96 and $35.69, and the stock now trades at $27.79, below her lowest exit price. Analysts see 87% upside from here. Someone is wrong.
- CAO Louise Frederika Kooij sold $6.71M across May, June, and July 2026; zero insider purchases in the same window.
- NAMS trades at $27.79, below the $29.96 floor of Kooij's sales, which topped out at $35.69 in May.
- $630M cash, zero debt, roughly four years of runway at -$143M annual operating cash outflow.
The Pattern in the Paperwork
Each of Kooij's three sale tranches followed the same structure: option exercises at strike prices of $10.00 to $11.90 per share on the same date, with share counts matching the subsequent open-market sales, a systematic cashless exercise pattern, per the Form 4 filings. That framing matters. Cashless exercise programs can reflect pre-arranged plans rather than discretionary bearishness. But the timing is notable: the May 26 sale at $35.69 per share generated $2.32 million, the June 22 tranche at $30.20 to $30.73 generated roughly $1.21 million, and the July 20 cluster at $29.96 to $31.71 added another $3.19 million, each tranche at a successively lower price, as the stock drifted down. The executive responsible for the books was not pausing to reassess at lower prices.
One Drug, Two Bets, No Revenue
NewAmsterdam Pharma, a Netherlands-based late-stage biopharmaceutical company with roughly 100 employees, is effectively a single-asset story: Obicetrapib, an oral CETP inhibitor in trials as both a monotherapy and a combination therapy with ezetimibe to lower LDL-C in cardiovascular disease patients. A Phase 2a trial for Alzheimer's disease gives the drug a second potential indication. Trailing twelve-month revenue is approximately $10 million, down 80.7% year-over-year, with 100% gross margins, consistent with milestone or licensing payments, not product sales. The company has missed Wall Street EPS estimates in three of the last four quarters, including a -55.1% surprise in the fourth-prior quarter and a -46.4% miss in the third-prior. Against that backdrop, NewAmsterdam Pharma Company N.V.'s latest numbers reflect a $3.25 billion market cap resting entirely on Obicetrapib's clinical outcome.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| NAMS | $3.3B | n/a | +11.1% |
| MLYS | $2.3B | n/a | +73.0% |
| EWTX | $4.7B | n/a | +191.5% |
| IRON | $3.0B | n/a | +30.6% |
| ELVN | $4.3B | n/a | +182.6% |
| APGE | $10.2B | n/a | +252.1% |
What to Watch Next
The institutional read cuts the other way. Investors hold 105.8% of NAMS float, implying significant short positions layered beneath long institutional holdings, while short interest sits at 9.9% of float. The analyst consensus target of $51.96 implies 87% upside from that level. Four 8-Ks disclosing officer departures or appointments in 120 days at a 100-person company, per SEC filings, adds a separate variable. The next significant checkpoint is clinical data on Obicetrapib, that outcome, not the insider transaction pattern, is what resolves the current price versus $51.96 argument. Insider ownership stands at 0.9%, so the company's upside accrues almost entirely to outside shareholders. Run the free NewAmsterdam Pharma Company N.V. deep-dive → at /stock/nams.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is Obicetrapib?
Obicetrapib is an oral CETP inhibitor in clinical trials at NewAmsterdam Pharma as both a monotherapy and a combination therapy with ezetimibe to lower LDL-C in cardiovascular disease patients. A Phase 2a trial for Alzheimer's disease adds a second potential indication. The company's $3.25 billion market cap rests entirely on Obicetrapib's clinical outcome.
Why did NewAmsterdam Pharma's CAO sell shares?
CAO Louise Frederika Kooij sold $6.71 million across May, June, and July 2026 through a cashless exercise pattern, exercising options at strike prices of $10.00 to $11.90 per share on the same dates as the open-market sales, consistent with a pre-arranged plan. Each tranche came at a successively lower price as the stock drifted down, from $35.69 in May to a range of $29.96 to $31.71 in July. The executive did not pause to reassess at lower prices.
What is the analyst price target for NewAmsterdam Pharma?
The analyst consensus price target is $51.96, implying 87% upside from the current price of $27.79. That target sits well above the $35.69 peak at which the CAO began selling, creating a notable divergence between insider selling behavior and the institutional outlook.
Does NewAmsterdam Pharma have revenue?
Trailing twelve-month revenue is approximately $10 million, down 80.7% year-over-year, with 100% gross margins consistent with milestone or licensing payments rather than product sales. The company has missed Wall Street EPS estimates in three of the last four quarters, including a -55.1% surprise in the fourth-prior quarter.
How much cash does NewAmsterdam Pharma have?
NewAmsterdam Pharma holds $630 million in cash with zero debt, providing roughly four years of runway at its annual operating cash outflow of $143 million. Insider ownership stands at 0.9%, so the company's potential upside accrues almost entirely to outside shareholders.
NewAmsterdam Pharma's Chief Accounting Officer sold $6.71 million in open-market stock across three months at prices ranging from $29.96 to $35.69 per share — and NAMS now trades at $27.79, below every price at which she exited. Analysts project 87% upside; the executive with the clearest view of the books was a persistent seller.